[go: up one dir, main page]

DK0482076T3 - Stabile vaccinepræparater indeholdende interleukiner - Google Patents

Stabile vaccinepræparater indeholdende interleukiner

Info

Publication number
DK0482076T3
DK0482076T3 DK90911344.1T DK90911344T DK0482076T3 DK 0482076 T3 DK0482076 T3 DK 0482076T3 DK 90911344 T DK90911344 T DK 90911344T DK 0482076 T3 DK0482076 T3 DK 0482076T3
Authority
DK
Denmark
Prior art keywords
preparations containing
vaccine preparations
interleukin
mineral
interleukins
Prior art date
Application number
DK90911344.1T
Other languages
English (en)
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0482076T3 publication Critical patent/DK0482076T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK90911344.1T 1989-07-14 1990-07-16 Stabile vaccinepræparater indeholdende interleukiner DK0482076T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14

Publications (1)

Publication Number Publication Date
DK0482076T3 true DK0482076T3 (da) 1995-07-17

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911344.1T DK0482076T3 (da) 1989-07-14 1990-07-16 Stabile vaccinepræparater indeholdende interleukiner

Country Status (12)

Country Link
EP (1) EP0482076B1 (da)
JP (2) JP3485184B2 (da)
KR (1) KR0177179B1 (da)
AT (1) ATE121629T1 (da)
AU (1) AU648509B2 (da)
CA (1) CA2063587C (da)
DE (1) DE69018990T2 (da)
DK (1) DK0482076T3 (da)
ES (1) ES2075900T3 (da)
FI (1) FI104233B (da)
NO (1) NO301577B1 (da)
WO (1) WO1991001143A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
EP0839536A1 (en) * 1989-10-27 1998-05-06 Arch Development Corporation Methods and compositions for promoting immunopotentiation
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
WO1992011030A1 (en) * 1990-12-19 1992-07-09 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
AU665762B2 (en) * 1991-05-13 1996-01-18 Regents Of The University Of California, The Liposomal polysaccharide vaccines
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
ATE151989T1 (de) * 1992-08-10 1997-05-15 Us Gov Health & Human Serv Interleukin-4 stimulierter t-lymphozyten-zelltod
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1996007102A1 (en) * 1994-09-01 1996-03-07 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
JP3737519B2 (ja) 1996-05-31 2006-01-18 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 百日咳菌ワクチン用アジュバントとしてのｉｌ―１２
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1196193B1 (en) 1999-12-03 2008-11-05 Celltech Chiroscience Limited Interleukin-1 mutein useful as vaccine adjuvant
SG163615A1 (en) 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US20090068254A1 (en) * 2005-09-30 2009-03-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
CA2890258C (en) * 2012-11-02 2020-10-20 Cytuvax Composition comprising cytokine macro-aggregates
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
US20220008515A1 (en) 2018-11-16 2022-01-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
KR20220150274A (ko) 2020-01-13 2022-11-10 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
KR20230104175A (ko) 2020-11-05 2023-07-07 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
KR0177179B1 (ko) 1999-03-20
JP3485184B2 (ja) 2004-01-13
FI104233B1 (fi) 1999-12-15
AU648509B2 (en) 1994-04-28
NO920161L (no) 1992-03-05
NO301577B1 (no) 1997-11-17
CA2063587A1 (en) 1991-01-15
KR920703103A (ko) 1992-12-17
DE69018990D1 (de) 1995-06-01
JP2004002463A (ja) 2004-01-08
EP0482076A1 (en) 1992-04-29
DE69018990T2 (de) 1995-12-14
JPH04506663A (ja) 1992-11-19
FI920132A0 (fi) 1992-01-13
ATE121629T1 (de) 1995-05-15
WO1991001143A1 (en) 1991-02-07
FI104233B (fi) 1999-12-15
ES2075900T3 (es) 1995-10-16
NO920161D0 (no) 1992-01-13
CA2063587C (en) 2005-08-30
AU6050090A (en) 1991-02-22
EP0482076B1 (en) 1995-04-26

Similar Documents

Publication Publication Date Title
DK0482076T3 (da) Stabile vaccinepræparater indeholdende interleukiner
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
MX9203294A (es) Factor de estimulacion de aniquilador natural.
AU6979387A (en) Fusion protein comprising influenza virus haemagglutinin and antigenic epitope
ATE61937T1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
ATE350390T1 (de) Synthetische peptide und impfstoffe welche diese beinhalten
DE60132427D1 (de) Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
NZ203190A (en) Vaccines of infections bronchitis virus
AU2415284A (en) Polypeptidic fractions inducing propective antibodies against malaria parasites and immunogenic compositions containing them
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
JPS55106261A (en) Composition made of dispersed body of colloid silica and colloid titania
AU567998B2 (en) Determination of polyvalent antigens
ATE44651T1 (de) Immunogene protein- oder peptidkomplexe enthaltende vakzine.
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
AU5343390A (en) Preparation of unassembled pilus subunits and vaccines containing them
ZA905296B (en) Use of bluetongue virus proteins as vaccines components
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.